2024
Prescription Drug Prices: An AAN Position Statement.
Santoro J, Sico J, Burke J, Sarkar K, Turbes M, Evans D, Jordan J. Prescription Drug Prices: An AAN Position Statement. Neurology 2024, 102: e209132. PMID: 38335469, DOI: 10.1212/wnl.0000000000209132.Peer-Reviewed Original ResearchConceptsHigh cost of medicationNeurological disordersDevelopment of novel therapeuticsNeurological diseasesOrphan Drug ActTherapeutic optionsCost of medicationsHigh-value careCost of prescription drugsPrescription drug pricesRare diseaseTreat rare diseasesPatientsNovel therapeuticsTreat neurological disordersDrug ActCost containment effortsChronic neurological conditionsEffective prescription medicationsMedicationPrescriber accessPrescription medicationsTherapyHealthcare systemApproval pathway
2018
Survey Analysis of the Use, Effectiveness, and Patient‐Reported Tolerability of Inhaled Oxygen Compared With Injectable Sumatriptan for the Acute Treatment of Cluster Headache
Schindler EAD, Wright DA, Weil MJ, Gottschalk CH, Pittman BP, Sico JJ. Survey Analysis of the Use, Effectiveness, and Patient‐Reported Tolerability of Inhaled Oxygen Compared With Injectable Sumatriptan for the Acute Treatment of Cluster Headache. Headache The Journal Of Head And Face Pain 2018, 58: 1568-1578. PMID: 30221765, DOI: 10.1111/head.13405.Peer-Reviewed Original ResearchConceptsInjectable sumatriptanCluster headacheAcute treatmentMedication responseOxygen deliverySide effectsPatient-reported side effectsSecondary analysisTherapeutic response rateCigarette smoking historyOptimization of therapyOptimal oxygen deliveryPositive predictorSmoking historyOxygen therapyCigarette smokingHeadache clinicTherapeutic optionsPatient populationPharmacologic interventionsTriptan medicationsComparable efficacyDaily attacksMale genderTherapeutic response